Boundless Bio, Inc. (NASDAQ: BOLD) is a biotechnology company. It recently announced a definitive merger agreement with Serapha Bio, Inc., a privately held firm. The combined company will operate as Serapha Bio. It will focus on advancing a program for Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder.
Amid these developments, a major insider is increasing their stake. On June 29, 2026, TANG KEVIN, a 10 percent owner of Boundless Bio, Inc., acquired 63,985 shares of common stock. The purchase was made at a price of $2.47 per share, bringing TANG KEVIN's total ownership to approximately 2.53 million shares.
This insider purchase occurs as Boundless Bio, Inc.'s stock price is priced at $2.45 per share, reflecting a daily drop of 4.30%. The company's market capitalization, which is the total value of all its shares, stands at about $55.06 million. The stock has traded between $0.96 and $2.79 over the past 52 weeks.
The merger is also under scrutiny. As highlighted by Business Wire, the law firm Halper Sadeh LLC is investigating the deal. The investigation questions if Boundless Bio, Inc. secured a fair price for its shareholders. Upon completion, current Boundless Bio, Inc. shareholders are expected to own only about 3.7% of the new combined company.
Despite the investigation, the merger is supported by significant financing. As reported by GlobeNewswire, a concurrent private placement of $230 million was announced. This funding is co-led by RTW Investments and RA Capital Management and will support the new company's research programs.
